IL282122A - Antibody variants and uses thereof - Google Patents
Antibody variants and uses thereofInfo
- Publication number
- IL282122A IL282122A IL282122A IL28212221A IL282122A IL 282122 A IL282122 A IL 282122A IL 282122 A IL282122 A IL 282122A IL 28212221 A IL28212221 A IL 28212221A IL 282122 A IL282122 A IL 282122A
- Authority
- IL
- Israel
- Prior art keywords
- mutation
- variant
- domain
- parent polypeptide
- antibody variants
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000004337 magnesium citrate Substances 0.000 abstract 1
- 239000001601 sodium adipate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
To provide polypeptides and related antibodies comprising a variant Fc domain.SOLUTION: The present invention provides a method of increasing an effector function of a parent polypeptide comprising an Fc-domain of an immunoglobulin and a binding region, the method comprising introducing a mutation to the parent polypeptide in at least one amino acid residue selected from those corresponding to E345, E430, S440, Q386, P247, I253, S254, Q311, D/E356, T359, E382, Y436, and K447 in the Fc-region of a human IgG1 heavy chain, with the proviso that the mutation in S440 is S440Y or S440W; a variant and composition thereof.SELECTED DRAWING: None
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161504994P | 2011-07-06 | 2011-07-06 | |
DKPA201100519 | 2011-07-06 | ||
DKPA201200371 | 2012-05-30 | ||
PCT/EP2012/063339 WO2013004842A2 (en) | 2011-07-06 | 2012-07-06 | Antibody variants and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL282122A true IL282122A (en) | 2021-05-31 |
Family
ID=67997265
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL230098A IL230098B (en) | 2011-07-06 | 2013-12-23 | Antibody variants and uses thereof |
IL282122A IL282122A (en) | 2011-07-06 | 2021-04-07 | Antibody variants and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL230098A IL230098B (en) | 2011-07-06 | 2013-12-23 | Antibody variants and uses thereof |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP2020055800A (en) |
KR (1) | KR20200120743A (en) |
IL (2) | IL230098B (en) |
ZA (1) | ZA201608707B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230144960A (en) * | 2022-04-07 | 2023-10-17 | 트윈피그바이오랩(주) | Immunotherapy drug based on new peptide |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2532910T3 (en) * | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Antibody variants and fragments thereof |
JP2008504002A (en) * | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto |
PT1706424E (en) * | 2004-01-12 | 2009-10-01 | Applied Molecular Evolution | Fc region variants |
WO2006104989A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
WO2008114011A2 (en) * | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
EP2352521B1 (en) * | 2008-10-14 | 2020-09-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
MX353144B (en) * | 2010-04-20 | 2017-12-20 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof. |
UA117901C2 (en) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
-
2012
- 2012-07-06 KR KR1020207028302A patent/KR20200120743A/en not_active Application Discontinuation
-
2013
- 2013-12-23 IL IL230098A patent/IL230098B/en active IP Right Grant
-
2016
- 2016-12-15 ZA ZA2016/08707A patent/ZA201608707B/en unknown
-
2019
- 2019-09-09 JP JP2019163535A patent/JP2020055800A/en active Pending
-
2021
- 2021-04-07 IL IL282122A patent/IL282122A/en unknown
- 2021-04-30 JP JP2021077015A patent/JP7509716B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20200120743A (en) | 2020-10-21 |
JP2020055800A (en) | 2020-04-09 |
ZA201608707B (en) | 2019-09-25 |
JP7509716B2 (en) | 2024-07-02 |
IL230098B (en) | 2021-06-30 |
JP2021120385A (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
RU2013140350A (en) | ANTIBODIES AGAINST HUMAN IL33R AND THEIR APPLICATION | |
IN2015DN01361A (en) | ||
EA201290413A1 (en) | MUTATED Fc ANTIBODIES WITH ELIMINATED EFFECTOR FUNCTIONS | |
EA201390923A1 (en) | MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD | |
WO2009131702A3 (en) | Antibodies against fcrn and use thereof | |
NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
EA201190132A1 (en) | HUMANIZED ANTIBODIES, CONNECTING CD19, AND THEIR APPLICATION | |
EA201490745A1 (en) | POLYPEPTIDES OF ANTIBODIES THAT CAUSE ANTAGONISM CD40L | |
WO2009048537A3 (en) | Humanized antibody | |
EA201591407A1 (en) | ANTIBODIES CONTAINING CHEMICAL CONSTANT DOMAINS | |
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
CA2953714C (en) | Anti-tnfa antibodies with ph-dependent antigen binding | |
TR201815254T4 (en) | ANTIBODIES CONNECTED TO TL1A AND THEIR USES | |
WO2012016073A3 (en) | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions | |
UA117901C2 (en) | Antibody variants and uses thereof | |
CR20120359A (en) | ANTI-IL-10 HUMANIZED ANTIBODIES FOR THE TREATMENT OF ERYTHEMATE SYSTEM LUPUS (SLE) | |
BR112014027659A2 (en) | cll-1 specific antibodies | |
WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
EA201391761A1 (en) | ANTI-ALPHA-SINUCLAIN-BINDING MOLECULES | |
NZ707327A (en) | Mice that make binding proteins comprising vl domains | |
BR112013026828A2 (en) | cd40 antagonizing antibody polypeptides | |
WO2008121615A3 (en) | Antibody formulation | |
EA202092884A1 (en) | COMPOSITIONS WITH HIGH ANTIBODY CONCENTRATION | |
WO2009081285A3 (en) | Hepatitis c virus antibodies |